Davide Campari-Milano


Q2 FY24 – Campari has caught the flu

01/08/24 -"Although Campari’s results have been relatively resilient against a backdrop of soft market dynamics, the lack of sunshine leading to a negative mix is weighing on the Italian company. ..."

Pages
52
Language
English
Published on
01/08/24
You may also be interested by these reports :
09/12/25
The FY2025 preliminary results were broadly in line with expectations. New categories revenue accelerated in H2, driven by oral nicotine pouches and ...

09/12/25
Ahead of Q4 2025, we reassessed HelloFresh’s profitability and have adopted a more cautious stance. Consequently, we have revised our Sales and EBIT ...

09/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...

27/11/25
Today’s call marked the first for the new CEO, Mr Franck Marilly. Despite results already exceeding expectations, he heightened anticipation by ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO